Materials & Resources » Chemicals | Cambrex Corp.

Cambrex Corp. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
22,745.00
45,518.00
43,974.00
74,141.00
183,284.00
96
Total Accounts Receivable
84,219.00
87,734.00
98,198.00
117,370.00
96,035.00
185
Inventories
89,965.00
85,630.00
109,920.00
123,184.00
138,542.00
111
Other Current Assets
5,631.00
8,688.00
7,187.00
7,960.00
4,217.00
18
Total Current Assets
202,560.00
227,570.00
259,279.00
322,655.00
422,078.00
410
Net Property, Plant & Equipment
171,966.00
163,567.00
186,487.00
217,092.00
254,299.00
361
Total Investments and Advances
13,364.00
665.00
-
-
-
-
Intangible Assets
42,681.00
52,814.00
38,754.00
55,123.00
57,494.00
448
Other Assets
7,667.00
4,032.00
1,760.00
3,934.00
3,496.00
3
Total Assets
458,037.00
487,072.00
505,539.00
611,865.00
740,565.00
1,223
ST Debt & Current Portion LT Debt
-
-
30,000.00
-
-
Accounts Payable
29,052.00
43,670.00
39,257.00
42,873.00
35,017.00
Income Tax Payable
98.00
189.00
-
9,469.00
43.00
Other Current Liabilities
68,121.00
54,920.00
60,545.00
43,120.00
47,481.00
Total Current Liabilities
97,271.00
98,779.00
129,802.00
95,462.00
82,541.00
Long-Term Debt
79,250.00
60,000.00
-
-
-
Provision for Risks & Charges
40,123.00
50,949.00
42,661.00
59,812.00
58,652.00
Deferred Taxes
6,964.00
27,879.00
11,524.00
6,140.00
4,608.00
Other Liabilities
18,338.00
15,573.00
14,506.00
44,243.00
46,702.00
Total Liabilities
247,817.00
235,846.00
194,704.00
206,438.00
195,701.00
Common Equity (Total)
210,220.00
251,226.00
310,835.00
405,427.00
544,864.00
Total Shareholders' Equity
210,220.00
251,226.00
310,835.00
405,427.00
544,864.00
Total Equity
210,220.00
251,226.00
310,835.00
405,427.00
544,864.00
Liabilities & Shareholders' Equity
458,037.00
487,072.00
505,539.00
611,865.00
740,565.00

About Cambrex

View Profile
Address
One Meadowlands Plaza
East Rutherford New Jersey 07073
United States
Employees -
Website http://www.cambrex.com
Updated 07/08/2019
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates.